Flightpath Biosciences licenses U. of I.-developed microbiome-sparing antibiotic Jul 8, 2025 11:30 am by Diana YatesInnovation Share on Facebook Tweet Email Images Professor Paul Hergenrother's team developed a class of antibiotic agents that target pathogenic gram-negative bacteria without harming beneficial microbes. The new compounds are being licensed for further testing and development. Share on Facebook Tweet Email